Want to see GB:VRCI full AI Analyst Report?
Verici Dx Plc (VRCI) AI Stock Analysis
Verici Dx Plc
(LSE:VRCI)
The score is primarily constrained by persistent losses, heavy cash burn, and funding dependence. Early revenue growth and low leverage provide some support, while mixed technical indicators and a negative P/E ratio limit the overall rating.
Verici Dx Plc (VRCI) vs. iShares MSCI United Kingdom ETF (EWC)
- Market Cap
- GBP 3.84M
- Dividend Yield
- ―
- Average Volume (3M)
- 9.12M
- Price to Earnings (P/E)
- -0.6
- Beta (1Y)
- -1.43
- Revenue Growth
- 77.87%
- EPS Growth
- 84.36%
- Country
- UK
- Employees
- 18
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Diagnostics & Research
Verici Dx Plc Business Overview & Revenue Model
Company Description
Verici Dx plc is an immuno-diagnostics company primarily focused on the kidney transplantation sector. The firm specializes in creating both predictive and diagnostic assays for patients who have undergone kidney transplants. Its development pipeline...
Verici Dx Plc Financial Statement Overview
Summary
Revenue growth and high gross profitability are offset by substantial operating losses, renewed cash-flow deterioration, cumulative losses, and dependence on external funding.
Income Statement
42NeutralBalance Sheet
46NeutralCash Flow
33Negative| Breakdown | TTM | Dec 2025 | Jun 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.50M | 3.74M | 3.34M | 1.01M | 0 | 0 |
| Gross Profit | 1.97M | 2.32M | 3.34M | 1.01M | 0 | 0 |
| EBITDA | -7.17M | ― | -5.15M | -7.88M | -10.50M | -7.15M |
| Net Income | -7.82M | -7.08M | -5.87M | -8.73M | -11.36M | -8.33M |
Balance Sheet | ||||||
| Total Assets | 8.19M | 7.94M | 7.49M | 7.44M | 14.30M | 13.79M |
| Cash, Cash Equivalents and Short-Term Investments | 2.41M | 3.34M | 4.06M | 2.65M | 9.80M | 10.34M |
| Total Debt | 776.01K | 197.07K | 371.00K | 540.00K | 700.00K | 0 |
| Total Liabilities | 2.45M | 1.44M | 2.23M | 3.88M | 2.80M | 1.80M |
| Stockholders Equity | 5.75M | 6.51M | 5.26M | 3.56M | 11.51M | 11.98M |
Cash Flow | ||||||
| Free Cash Flow | -8.35M | -8.39M | -6.21M | -7.39M | -11.38M | -7.30M |
| Operating Cash Flow | -8.34M | -8.39M | -6.02M | -7.16M | -10.07M | -6.34M |
| Investing Cash Flow | -222.62K | -192.97K | 61.00K | -231.00K | -1.31M | -965.86K |
| Financing Cash Flow | 10.75M | 7.87M | 7.32M | -27.00K | 12.67M | -73.55K |
Verici Dx Plc Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:VRCI, the sentiment is Positive. The current price of 0.23 is above the 20-day moving average (MA) of 0.22, above the 50-day MA of 0.22, and below the 200-day MA of 0.41, indicating a neutral trend. The MACD of -0.00 indicates Negative momentum. The RSI at 56.48 is Neutral, neither overbought nor oversold. The STOCH value of 40.26 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:VRCI.
Verici Dx Plc Peers Comparison
Overall Rating
GB:EKF64Neutral
GB:GDR49Neutral
GB:ABDX46Neutral- GB:VRCI41Neutral
GB:OBD40Underperform
GB:RENX40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| GB:EKF | 64Neutral | GBP 102.71M | 41.38 | 3.58% | ― | 2.26% | -57.04% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| GB:GDR | 49Neutral | GBP 15.65M | -0.89 | -1044.57% | ― | 65.60% | 74.84% |
| GB:ABDX | 46Neutral | GBP 22.75M | -16.36 | -34.31% | ― | 30.42% | 43.16% |
| GB:VRCI | 41Neutral | GBP 15.32M | -0.60 | -127.57% | ― | 77.87% | 84.36% |
| GB:OBD | 40Underperform | GBP 14.45M | -0.27 | -451.74% | ― | 33.37% | 86.41% |
| GB:RENX | 40Underperform | GBP 36.54M | -3.44 | 675.00% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GB:VRCI | Verici Dx Plc | 0.23 | -0.45 | -65.93% | |
| GB:EKF | EKF Diagnostics Holdings | 24.00 | -2.20 | -8.40% | |
| GB:GDR | Genedrive plc | 0.97 | 0.01 | 1.25% | |
| GB:OBD | Oxford BioDynamics | 0.11 | -0.21 | -66.56% | |
| GB:RENX | Renalytix Plc OTC | 5.45 | -1.93 | -26.15% | |
| GB:ABDX | Abingdon Health PLC | 9.00 | 2.75 | 44.00% |
Verici Dx Plc Corporate Events
Verici Dx Raises £8.5m Through AIM Placing and Retail Offer
PositiveVerici Dx plc has completed a WRAP Retail Offer at an issue price of £0.002 per share, raising approximately £250,000 in gross proceeds, which will be accompanied by a much larger institutional placing. Together, the placing and retail offe...
Verici Dx Raises £8.75m and Restores AIM Trading After Capital Access Window
PositiveVerici Dx plc, a developer of AI-driven kidney transplant diagnostics, offers a suite of personalised tests that support clinicians in assessing patient and organ response risk, aiming to improve transplant outcomes. The company’s technology is...
Verici Dx Calls General Meeting to Approve New Share Issuance After Fundraising
PositiveVerici Dx has published a circular and convened a general meeting for 27 October at Shoosmiths LLP in London, aiming to secure shareholder approval for additional share issuance authorities. The move follows a recently announced fundraising and is in...
Verici Dx Opens WRAP Retail Offer Alongside £8.5m Placing
PositiveVerici Dx has launched a WRAP retail offer to raise up to £250,000 by issuing as many as 125,000,000 new ordinary shares at £0.002 each, matching the price of its recently completed £8.5 million placing. The retail offer is aimed at gi...
Verici Dx Raises £8.5m in Oversubscribed Share Placing on AIM
PositiveVerici Dx has conditionally raised gross proceeds of £8.5 million through a placing of 4.25 billion new shares at 0.20 pence, an 11.1% discount to the pre-suspension market price. The fundraising, supported by both existing and new institutional...
Verici Dx closes accelerated bookbuild for new share placing
PositiveVerici Dx plc, a specialist in advanced clinical diagnostics for organ transplant patients, has announced the successful close of its accelerated bookbuild for a share placing. The placing, run with Singer Capital Markets and Oberon Capital as joint...
Verici Dx launches £8m share placing to fund U.S. transplant diagnostics push
NeutralVerici Dx plans to raise about £8 million through a heavily dilutive placing of 4 billion new shares at 0.2 pence, alongside a separate UK retail offer of up to £250,000, to bolster its balance sheet and support commercial expansion. The fu...
Verici Dx to Tap AIM Capital Access Window for New Equity Raise
PositiveVerici Dx plc, traded on AIM as VRCI, develops AI-assisted clinical diagnostic tests for organ transplantation, centred on a kidney transplant platform that uses transcriptomic analysis to generate RNA-based immune and pathway signatures. These leadi...
Verici Dx boosts Tutivia growth and expands transplant diagnostics footprint
PositiveVerici Dx reported H1 2026 revenues of $1.8m, broadly flat year-on-year as prior licensing income rolled off, but with Tutivia testing revenue up more than 50% and testing volumes rising despite a national slowdown in kidney transplants. The group po...
Verici Dx to Launch AI-Driven Transplant Genetic Test in Q4 2026
PositiveVerici Dx plc plans to launch TranscripTx, a first-in-class genetic test for transplant patients, in the fourth quarter of 2026, expanding its portfolio of advanced clinical diagnostics. The test uses next-generation sequencing on peripheral blood RN...
Verici Dx Gains Olink Certification to Expand Proteomics and Biomarker Services
PositiveVerici Dx has been designated an Olink Certified Service Provider, enabling it to offer Olink-based proteomics assay services from its CAP-certified and CLIA-accredited laboratory. This status allows the company to support biomarker discovery, algori...
Verici Dx Secures Shareholder Backing as All AGM Resolutions Pass
PositiveVerici Dx plc, a developer of advanced clinical diagnostics for transplant patients, reported that all resolutions put to shareholders at its latest Annual General Meeting were approved. The strong voting support across resolutions underscores shareh...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 17, 2026